Investment Thesis
Rapid Micro Biosystems faces severe fundamental challenges with catastrophic unit economics (4.6% gross margin) and unsustainable cash burn ($15.1M operating outflow annually) against minimal cash reserves of $13.8M, leaving less than one year of runway. Despite 19.7% revenue growth, the company loses $1.78 for every dollar of revenue generated, indicating growth destroying shareholder value rather than building it.
Strengths
- Revenue growing 19.7% year-over-year showing market demand
- Adequate short-term liquidity with 2.57x current ratio
- Positive stockholders' equity of $20.4M providing some capital cushion
Risks
- Operating cash burn of $15.1M annually with only $13.8M cash on hand (sub-one-year runway)
- Critically low 4.6% gross margin indicates severe unit economics and pricing power problems
- Cannot service $19.1M debt load from operations with negative interest coverage of -659.6x, creating refinancing risk
- Negative operating margin of -173.1% means business model is fundamentally broken; growth is value-destructive
- Company burns $1.78 for every dollar of revenue, unsustainable without major restructuring or capital infusion
Key Metrics to Watch
- Gross margin trend (must improve to >25% minimum for viability)
- Monthly cash burn rate and remaining runway duration
- Operating cash flow path to positive (critical within 6 months)
- Debt refinancing needs and covenant compliance status
Financial Metrics
Revenue
8.0M
Net Income
-14.3M
EPS (Diluted)
$-0.31
Free Cash Flow
-15.5M
Total Assets
62.4M
Cash
13.8M
Profitability Ratios
Gross Margin
4.6%
Operating Margin
-173.1%
Net Margin
-178.4%
ROE
-70.0%
ROA
-22.9%
FCF Margin
-193.1%
Balance Sheet & Liquidity
Current Ratio
2.57x
Quick Ratio
1.66x
Debt/Equity
0.93x
Debt/Assets
67.3%
Interest Coverage
-659.62x
Long-term Debt
19.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T07:26:04.204610 |
Data as of: 2026-03-31 |
Powered by Claude AI